The WNT pathway bifurcates into canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) branches, each intricately orchestrating cellular fate decisions. Central to the canonical pathway is the regulation of β-catenin stability, which translocates to the nucleus upon activation to co-activate transcription factors crucial for oncogenic gene expression. Non-canonical signaling, meanwhile, modulates cytoskeletal dynamics and cell polarity, influencing tumor invasiveness and microenvironment interactions. Crosstalk between WNT signaling and other critical pathways such as Notch, Hedgehog, and TGF-β further complicates therapeutic targeting, underscoring the necessity for nuanced molecular interventions.

Cancer types including breast, colorectal, liver, glioblastoma, and prostate cancers exhibit aberrant WNT activity, albeit through distinct molecular mechanisms. For instance, mutations in components like APC, β-catenin, or RNF43 lead to constitutive activation of canonical WNT signaling in colorectal cancer, driving unchecked cell proliferation. Conversely, in glioblastoma, non-canonical pathways predominate, fostering an aggressive phenotype characterized by enhanced migratory capacity. Understanding these cancer-specific variations is critical for designing tailored therapeutic approaches.

Therapeutically, the WNT axis offers multiple “druggable” targets, from ligand production enzymes like Porcupine (PORCN) to receptor complexes comprising Frizzled (FZD) and LRP5/6, along with downstream effectors such as Dishevelled (DVL) and Tankyrase (TNKS). The development of Porcupine inhibitors, which impede WNT ligand secretion, has shown promise in reducing tumor growth in preclinical models. Similarly, antagonists against FZD receptors and monoclonal antibodies targeting WNT ligands or their co-receptors have entered clinical trials with variable success.

However, the therapeutic exploitation of WNT signaling is profoundly challenged by “on-target” toxicities. WNT signaling’s role in normal tissue maintenance, particularly in bone homeostasis and gastrointestinal epithelium renewal, means its inhibition can precipitate severe adverse effects, including osteopenia and intestinal dysfunction. These toxicities pose substantial barriers to the clinical adoption of WNT pathway inhibitors, necessitating a delicate balance between anti-tumor efficacy and preservation of physiological functions.

To circumvent these challenges, emerging strategies focus on enhancing drug specificity and delivery. Advances in biomarker discovery enable the identification of patient subsets most likely to benefit from WNT-targeted therapies, thereby personalizing treatment. Moreover, combination regimens that integrate WNT inhibitors with immune checkpoint blockade or chemotherapeutic agents hold potential to amplify anti-cancer responses while mitigating individual drug toxicities.

The intricate regulation of WNT signaling is further complicated by the β-catenin/TCF transcriptional complex and its interaction with co-factors such as CREB-binding protein (CBP). Pharmacologic disruption of these protein-protein interactions represents a promising approach, aiming to selectively inhibit oncogenic transcriptional programs while sparing normal cellular signaling. Small molecule CBP inhibitors are currently undergoing evaluation for their efficacy and safety profiles.

Non-canonical WNT pathway components also present unique therapeutic opportunities. Modulating intracellular kinases like casein kinase 1 (CK1) or components involved in cytoskeletal rearrangement may attenuate metastatic potential without substantially affecting β-catenin-driven transcription in normal tissues. These approaches could offer safer yet effective avenues for blocking WNT-driven tumor progression.

The review also emphasizes the importance of understanding the tumor microenvironment’s contribution to WNT signaling dynamics. Tumor-associated stromal cells, immune infiltrates, and extracellular matrix components can modulate WNT pathway activity, influencing therapeutic responsiveness. Hence, future research must integrate microenvironmental cues to refine therapeutic designs further.

Leveraging high-throughput screening and omics technologies, researchers are mapping the complex networks of WNT-related molecular interactions, enabling rational design of next-generation inhibitors. These inhibitors may possess improved pharmacokinetic properties, enhanced tumor selectivity, and lower propensity for resistance development.

In conclusion, while significant hurdles remain, the growing elucidation of WNT signaling’s multifaceted roles in cancer provides a promising framework for innovative therapies. By integrating molecular biology, pharmacology, and clinical sciences, the field is poised to deliver targeted anti-cancer strategies that harness WNT signaling’s oncogenic potential while minimizing collateral tissue damage. The ongoing evolution of this avenue holds transformative promise for cancer patients worldwide.

Subject of Research: WNT signaling pathway in cancer and therapeutic targeting strategies.

Article Title: WNT signaling in cancer: molecular mechanisms and potential therapies.

News Publication Date: 22-Oct-2025

Web References: DOI: 10.1186/s43556-025-00327-x

Image Credits: Jing Li

Keywords: WNT signaling, cancer therapy, Porcupine inhibitors, β-catenin, Frizzled receptors, Tankyrase inhibitors, molecular oncology, pathway targeting, drug toxicity, tumor microenvironment, signal transduction, precision medicine

High-throughput short-read sequencing has long been the standard approach in both research and clinical genomics due to its high accuracy and throughput. Nevertheless, short-read platforms encounter major hurdles when mapping reads to repetitive or highly rearranged genomic regions, often resulting in inadequate sensitivity to detect certain classes of structural variants. Particularly in cancer, where genomes are riddled with somatic rearrangements and exhibit complex, often unbalanced karyotypes, short reads frequently fail to capture the full landscape of genomic alterations. Long-read sequencing, by contrast, offers reads spanning thousands to even millions of base pairs, ameliorating mapping ambiguities and enabling the phasing of variants on the same haplotype. Yet, despite these advantages, existing long-read SV callers generally lack adaptations specific to cancer genomes, limiting their utility in somatic mutation detection and complex rearrangement characterization.

Severus, as introduced by Keskus and colleagues in their latest publication in Nature Biotechnology, bridges this critical gap by introducing a breakpoint graph-based algorithm explicitly designed to analyze somatic SVs in cancer genomes. By integrating matching normal samples with tumor data, Severus effectively distinguishes somatic alterations from germline variants, enhancing accuracy in somatic variant identification. This methodological innovation is crucial because it prevents the misclassification of inherited polymorphisms as cancer-related changes, a common source of false positives in mutation calling.

One of Severus’s most remarkable features lies in its ability to handle unbalanced cancer karyotypes. Unlike balanced rearrangements which maintain overall genomic content, unbalanced karyotypes involve gains or losses of chromosomal material—a hallmark of malignancies. Severus’s algorithm accounts for these complex genomic states, allowing for more comprehensive detection and characterization of structural alterations relevant to tumor biology. This capacity to discern both balanced and unbalanced rearrangements underscores the algorithm’s sophistication in mirroring the biological realities of cancer genomes.

The core computational framework of Severus employs breakpoint graphs, a mathematical representation that elegantly captures the connections and adjacency between disrupted genomic segments. This graph-based approach allows the algorithm to systematically identify clusters of breakpoints, thereby reconstructing intricate rearrangement patterns that might be overlooked by linear or read-based methods. Through iterative graph traversals and haplotype phasing, Severus can elucidate multi-breakpoint SV events, providing a detailed reconstruction of tumor-specific genomic architectures.

Benchmarking Severus against a comprehensive panel of cancer cell lines analyzed using multiple sequencing technologies revealed its consistent superiority over both long-read and short-read SV callers. Metrics such as the F1 score, which harmonizes precision and recall, demonstrated that Severus delivered heightened sensitivity without sacrificing specificity. These improvements position Severus as a compelling tool for research laboratories and clinical genomics facilities aiming for accurate SV detection in complex cancer genomes.

Notably, the study highlighted how short-read sequencing systematically misses certain classes of somatic SVs that Severus unmasked with its long-read based methodology. Insertions, often difficult to capture without sufficiently long reads spanning the entire inserted fragment, were under-detected in short-read datasets. Likewise, clustered rearrangements—multiple breakpoints occurring in close proximity—pose challenges for traditional analysis pipelines but were effectively resolved by Severus’s breakpoint graph modeling. This revelation underscores the need to integrate long-read sequencing in cancer diagnostics for a more comprehensive mutation landscape.

The clinical utility of Severus was further exemplified in a series of pediatric leukemia and lymphoma cases. By applying the algorithm to these clinical samples, researchers uncovered cryptic rearrangements—genomic alterations that standard targeted panels and short-read sequencing overlooked. These hidden rearrangements hold considerable significance, as such mutations may bear diagnostic, prognostic, or therapeutic implications that impact patient management. Severus thus opens new avenues for precision medicine by facilitating the discovery of novel or rare SVs with potential clinical relevance.

Beyond its effectiveness, Severus also contributes to the broader understanding of cancer genome architecture and heterogeneity. Traditional SV callers often collapse signals from mixed tumor populations, which limits the granularity of subclonal analyses. By producing haplotype-specific SV calls, Severus allows for the identification of subpopulations within tumors, illuminating the evolutionary dynamics and intratumoral heterogeneity that underlie cancer progression and drug resistance. This capability is essential for developing adaptive treatment strategies and monitoring tumor evolution over time.

From a bioinformatics perspective, integrating Severus into existing sequencing workflows represents a paradigm shift. It challenges laboratories to reconsider data generation protocols, incorporating long-read platforms such as Oxford Nanopore Technologies (ONT) or Pacific Biosciences (PacBio), which offer the necessary read lengths to maximize Severus’s capabilities. Although long-read sequencing historically carried higher error rates and costs, continuous improvements in accuracy and decreasing expenses are rapidly making its application more feasible in clinical settings.

The implications of Severus extend beyond oncology; the algorithm’s core concepts could be adapted to other domains where structural genome variations play a critical role, such as congenital disorders or complex infectious diseases. However, cancer’s intrinsic genomic complexity—with variable ploidy, chromothripsis, and kataegis phenomena—poses unique computational opportunities and challenges that Severus adeptly addresses.

Severus’s development exemplifies the growing trend of synergy between cutting-edge sequencing technology and specialized computational tools tailored to distinct biological questions. By focusing specifically on somatic SVs in cancer, the algorithm fills an important niche that generic SV callers cannot satisfy completely. This precision is particularly essential in cancer genomics, where every variant carries potential clinical weight.

Looking ahead, broader adoption and further validation of Severus in diverse tumor types and clinical contexts will be instrumental in setting new standards for somatic SV detection. Extensions of the algorithm might incorporate episomal DNA analysis, integration with single-cell long-read sequencing, or real-time mutation calling for rapid diagnostics. Furthermore, community efforts to establish standardized benchmarking datasets and open-source tool development will facilitate iterative improvements and widespread accessibility.

In sum, Severus represents a transformative advancement in cancer genomics, offering an unprecedented ability to resolve complex somatic structural variants by harnessing the power of long-read sequencing combined with a mathematically rigorous breakpoint graph framework. Its clinical applications promise to unmask previously hidden genomic alterations, refine personalized treatment strategies, and ultimately improve patient outcomes. As long-read technologies increasingly permeate clinical practice, solutions like Severus will become indispensable tools in the genomic oncology arsenal, propelling precision medicine into new territories of accuracy and comprehensiveness.

Subject of Research: Somatic structural variation detection and complex rearrangement characterization in cancer genomes using long-read sequencing.

Article Title: Severus detects somatic structural variation and complex rearrangements in cancer genomes using long-read sequencing.

Article References:
Keskus, A.G., Bryant, A., Ahmad, T. et al. Severus detects somatic structural variation and complex rearrangements in cancer genomes using long-read sequencing. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02618-8

Image Credits: AI Generated